Compare Direxion Daily Semiconductor Bull 3X Shares (SOXL) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Direxion Daily Semiconductor Bull 3X Shares vs Spyre Therapeutics Inc. Common Stock — how do they compare? Direxion Daily Semiconductor Bull 3X Shares trades at $103.99 (market cap $20.78B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Direxion Daily Semiconductor Bull 3X Shares is far larger — about 2.8× Spyre Therapeutics Inc. Common Stock's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, Direxion Daily Semiconductor Bull 3X Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Direxion Daily Semiconductor Bull 3X Shares for 15 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| SOXL | SYRE | |
|---|---|---|
Market Cap | $20.78B | $7.52B |
Volume | 78,745,280 | 1,441,031 |
Sector | Leveraged / Inverse | Health |
52-Week High | $300.77 | $108.92 |
52-Week Low | $30.81 | $22.18 |
Typical Hold Time | 15 Days | 0 Days |
Enterprise Value | — | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SOXL (Direxion Daily Semiconductor Bull 3X ETF) trades at $127.57, down 0.65% on the day, with a bearish technical signal from moving averages. The ETF, which provides 3x leveraged exposure to semiconductor stocks, faces volatility amid mixed sentiment on chip sector prospects. Recent news highlights sector rallies and sharp declines, reflecting the amplified risk of leveraged products. Key support sits at $125, with resistance at $130.
Outlook is cautious due to leveraged structure and semiconductor cyclicality. Opportunities exist for tactical traders betting on AI-driven chip demand, but risks include sector volatility, regulatory tariffs, and erosion from daily rebalancing. Long-term holders face significant decay risk in volatile markets.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Direxion Daily Semiconductor Bull 3X Shares
SOXL is a leveraged ETF that seeks daily investment results corresponding to 300% of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bullish (long) position on the semiconductor sector. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXL →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
